Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenalidomide, Bortezomib, and Dexamethasone Combination Therapy as Induction Followed by Ixazomib and Lenalidomide Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

Trial Profile

Lenalidomide, Bortezomib, and Dexamethasone Combination Therapy as Induction Followed by Ixazomib and Lenalidomide Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jan 2019 Planned initiation date changed from 1 Jan 2019 to 10 Jan 2019.
    • 23 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Jan 2019.
    • 28 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top